Glenmark defends price of its COVID-19 drug favipiravir version
Image Credit: shortpedia
Glenmark Pharmaceuticals Ltd defended the pricing of its generic version of favipiravir, FabiFlu, on Tuesday, after India`s drug regulator had reportedly sent the company a notice on overpricing. Shares of the Mumbai-based company fell as much as 5.8% on Monday after local media reports said the Drug Controller General of India (DCGI) pulled up Glenmark regarding the price of the tablet and other concerns.